Erudio Healtherudio.com
Sponsor
Jiangsu HengRui Medicine trials: what clinicians said in public
No HCP commentary report on a trial sponsored by Jiangsu HengRui Medicine yet. Erudio has found public clinician commentary on 7 clinical trials sponsored by Jiangsu HengRui Medicine, including CameL-Sq, HORIZON-Breast06, HORIZON-Lung and NCT05320692. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (Jiangsu HengRui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| HORIZON-Breast06 NCT05814354 · Jiangsu HengRui Medicine Co., Ltd. DeepView → | HER2-low expressing recurrent/metastatic breast cancer | Phase 3 | Deep | View | |||
| HORIZON-Lung NCT04818333 · Jiangsu HengRui Medicine Co., Ltd. StandardView → | advanced HER2-mutant non-small cell lung cancer | Phase 1/Phase 2 | Standard | View | |||
| CameL-Sq NCT03668496 · Jiangsu HengRui Medicine Co., Ltd. FocusedView → | first-line stage IV squamous NSCLC | Phase 3 | Focused | View | |||
| NCT05320692 NCT05320692 · Jiangsu HengRui Medicine Co., Ltd. FocusedView → | incurable hepatocellular carcinoma | Phase 3 | Focused | View | |||
| NCT05533463 NCT05533463 · Jiangsu HengRui Medicine Co., Ltd. FocusedView → | advanced KRAS G12D-mutant solid tumors | Phase 1 | Focused | View | |||
| NCT05701709 NCT05701709 · Shanghai Hengrui Pharmaceutical Co., Ltd. FocusedView → | pretreated advanced solid tumors | Phase 1 | Focused | View | |||
| CAPTAIN-1st NCT03707509 · Jiangsu HengRui Medicine Co., Ltd. FocusedView → | first-line recurrent or metastatic nasopharyngeal carcinoma | Phase 3 | Focused | View | |||